Instead of only seeking disease-causing genes, Regeneron's primary strategy is to find rare protective mutations in individuals they call "superhumans." These people, naturally protected from diseases like heart attacks, provide a validated blueprint for new drugs. The company has already found over 50 such protective factors.

Human genetics doesn't just provide a drug target; it often specifies the therapeutic approach required. Discovering a protective loss-of-function mutation immediately tells researchers to develop an inhibitor (like an antibody or siRNA), accelerating the path from target discovery to molecule design.

Regeneron identified the main constraint in drug discovery as a lack of validated targets, not a shortage of advanced therapeutic tools. Their genetics engine was created to explore the 90% of the human genome that was untargeted by existing or experimental medicines, aiming to solve this core problem.

Regeneron's focus on diverse populations is a core research strategy. Key discoveries, like the PCSK9 heart disease mutation, were only possible because they were significantly more common in African Americans. This proves that diverse genomic data unlocks unique and powerful therapeutic targets that would otherwise be missed.

Regeneron's Genetics Center is a key competitive advantage, functioning as a discovery engine for new drug targets. By sequencing millions of patient genomes and linking them to health records, it allows Regeneron to identify novel genetic variants associated with diseases, feeding its antibody development pipeline with proprietary targets.

Regeneron's genetics engine created so many new targets that it revealed a strategic weakness: two-thirds were intracellular and untreatable with its world-class antibody platform. This success forced the company to "reinvent itself" and invest heavily in new modalities like sRNA and gene therapy to capitalize on its own discoveries.

Regeneron systematically expands the market for its drugs through "indication expansion." By identifying people in its database with a natural loss-of-function variant for a drug's target, they can scan thousands of diseases to see what other conditions these people are protected from, revealing new therapeutic opportunities.

While the industry success rate for drugs entering the clinic is only about 10%, programs with human genetics backing have a 2-3x higher probability of approval. Regeneron reports its success rate is even higher, at four to five times the baseline, due to its strict focus on large-effect genetic signals.

The primary bottleneck in drug development isn't creating therapies but identifying the right targets. Regeneron built its massive genetics database to find rare, protective genetic mutations in humans, effectively de-risking the target identification process and aiming to improve the industry's low success rate.